91641-02-0

Basic information

• Product Name: 1,2,3,4-TETRAHYDROQUINOLINEPROPIONIC ACID
• Synonyms: 1,2,3,4-TETRAHYDROQUINOLINEPROPIONIC ACID
• CAS NO: 91641-02-0
• Molecular Formula: C12H15NO2
• Molecular Weight: 0
• Mol File: 91641-02-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 399.1°Cat760mmHg
• Flash Point: 195.2°C
• Appearance: /
• Density: 1.165g/cm³
• Vapor Pressure: 4.37E-07mmHg at 25°C
• Refractive Index: 1.567
• CAS DataBase Reference: 1,2,3,4-TETRAHYDROQUINOLINEPROPIONIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDROQUINOLINEPROPIONIC ACID(91641-02-0)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDROQUINOLINEPROPIONIC ACID(91641-02-0)

Safety Data

• Hazardous Substances Data: 91641-02-0(Hazardous Substances Data)

Usage

Chemical classification

1,2,3,4-Tetrahydroquinolinepropionic acid is a chemical compound that is a derivative of quinoline and a propionic acid.

Molecular structure

It has a molecular structure that is similar to that of the neurotransmitter dopamine.

Pharmaceutical applications

It has potential pharmaceutical applications, as it has been studied for its potential as an anti-inflammatory and analgesic agent.

Preclinical research

It has shown promise in preclinical research for its ability to reduce pain and inflammation.

Neuroprotective effects

It has also been investigated for its potential neuroprotective effects and as a potential treatment for neurodegenerative diseases.

Further research needed

Further research is needed to fully understand the potential therapeutic applications of 1,2,3,4-tetrahydroquinolinepropionic acid and its derivatives.

Type of compound

It is a chemical compound with potential pharmaceutical applications.

Main uses

It has been studied for its potential as an anti-inflammatory and analgesic agent, and for its potential neuroprotective effects and as a potential treatment for neurodegenerative diseases.

Current status

It is not yet fully understood and requires further research to determine its potential therapeutic applications.

InChI:InChI=1/C12H15NO2/c14-12(15)7-9-13-8-3-5-10-4-1-2-6-11(10)13/h1-2,4,6H,3,5,7-9H2,(H,14,15)

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 3395-91-3 Methyl 3-bromopropionate 
• 2637-29-8 N-(β-cyanoethyl)-1,2,3,4-tetrahydroquinoline 
• 292638-85-8 acrylic acid methyl ester 

Downstream Products

• 51315-09-4 julolidin-1-one 
• 1051934-79-2 C₁₈H₂₀N₂O 
• 7093-26-7 5,6,8,14-tetrahydro-4H-benzo[b]quino[1,8-gh][1,6]naphthyridinylium betaine 
• 500870-15-5 5,6-dihydro-4H,8H-benzo[b]quino[1,8-gh][1,6]naphthyridine-9-carboxylic acid 

Relevant articles and documents

The optimization of a novel selective antagonist for human M2 muscarinic acetylcholine receptor

Muscarinic acetylcholine receptors (mAChRs) comprise five distinct subtypes denoted M1 to M5. The antagonism of M2 subtype could increase the release of acetylcholine from vesicles into the synaptic cleft and improve postsynaptic functions in the hippocampus via M1 receptor activation, displaying therapeutic potentials for Alzheimer's disease. However, drug development for M2 antagonists is still challenged among different receptor subtypes. In this study, by optimizing a scaffold from virtual screening, we synthesized two focused libraries and generated up to 50 derivatives. By measuring potency and binding selectivity, we discovered a novel M2 antagonist, ligand 47, featuring submicromolar IC50, high M2/M4 selectivity (~30-fold) and suitable lipophilicity (cLogP = 4.55). Further study with these compounds also illustrates the structure–activity relationship of this novel scaffold. Our study could not only provide novel lead structure, which was easy to synthesize, but also offer valuable information for further development of selective M2 ligands.

Microbiological Transformations, Part 9. Microbiological Transformations of 1,2,5,6-Tetrahydropyrroloquinolin-4-one and of Derivatives of 1,2,3,5,6,7-Hexahydropyridoquinoline with the Fungus Cunninghamella elegans

Incubation of 1,2,6,7-tetrahydropyridoquinolin-3(5H)-one with C. elegans resulted in oxidation at the C-7 benzylic position, whereas 1-methyl-1,2,6,7-tetrahydropyridoquinolin-5(3H)-one gave products resulting from oxidation at both benzylic positions. cis- and trans-1-Hydroxy-3-methyl-1,2,6,7-tetrahydropyridoquinolin-5(3H)-ones were produced on incubation of 5-methyl-1,2,6,7-tetrahydropyridoquinolin-3(5H)-one with C. elegans, in addition to trans-1-hydroxy-5-methyl-1,2,6,7-tetrahydropyridoquinolin-3(5H)-one.Incubation of 1,2,5,6-tetrahydropyrroloquinolin-4-one with C. elegans resulted in dehydrogenation to 1,2-dihydropyrroloquinolin-4-one.Incubation of 2,3,6,7-tetrahydropyridoquinolin-1(5H)-one with C. elegans resulted in benzylic attack at C-7.